These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22332457)

  • 1. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
    Wu EQ; Ben-Hamadi R; Lu M; Beaulieu N; Yu AP; Erder MH
    Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.
    Wu E; Greenberg PE; Yang E; Yu A; Erder MH
    Curr Med Res Opin; 2008 Sep; 24(9):2587-95. PubMed ID: 18674407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
    Wu E; Greenberg P; Yang E; Yu A; Ben-Hamadi R; Erder MH
    Curr Med Res Opin; 2008 Oct; 24(10):2805-13. PubMed ID: 18755054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.
    Wu EQ; Greenberg PE; Yang E; Yu AP; Ben-Hamadi R; Erder MH
    J Med Econ; 2009 Jun; 12(2):124-35. PubMed ID: 19566483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.
    Wu EQ; Ben-Hamadi R; Yu AP; Tang J; Haim Erder M; Bose A
    J Med Econ; 2010; 13(2):314-23. PubMed ID: 20504111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
    Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
    J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
    Hemels ME; Kasper S; Walter E; Einarson TR
    Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
    J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.
    Ivanova JI; Birnbaum HG; Chen L; Duhig AM; Dayoub EJ; Kantor ES; Schiller MB; Phillips GA
    Am J Manag Care; 2011 Aug; 17(8):e314-23. PubMed ID: 21851139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.
    Wu EQ; Greenberg PE; Ben-Hamadi R; Yu AP; Yang EH; Erder MH
    Am Health Drug Benefits; 2011 Mar; 4(2):78-87. PubMed ID: 25126340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM; Fernandez JL
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
    McLaughlin TP; Eaddy MT; Grudzinski AN
    Clin Ther; 2004 Jan; 26(1):115-24. PubMed ID: 14996524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.